Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Surfactant protein D deficiency influences allergic immune responses.
Schaub B, Westlake RM, He H, Arestides R, Haley KJ, Campo M, Velasco G, Bellou A, Hawgood S, Poulain FR, Perkins DL, Finn PW. Schaub B, et al. Among authors: velasco g. Clin Exp Allergy. 2004 Dec;34(12):1819-26. doi: 10.1111/j.1365-2222.2004.02068.x. Clin Exp Allergy. 2004. PMID: 15663554
Toll-like receptor 4 or 2 agonists decrease allergic inflammation.
Velasco G, Campo M, Manrique OJ, Bellou A, He H, Arestides RS, Schaub B, Perkins DL, Finn PW. Velasco G, et al. Am J Respir Cell Mol Biol. 2005 Mar;32(3):218-24. doi: 10.1165/rcmb.2003-0435OC. Epub 2004 Dec 2. Am J Respir Cell Mol Biol. 2005. PMID: 15576672
[Genetic diseases of epigenetic machinery].
de Dieuleveult M, Velasco G. de Dieuleveult M, et al. Among authors: velasco g. Med Sci (Paris). 2024 Dec;40(12):914-924. doi: 10.1051/medsci/2024181. Epub 2024 Dec 20. Med Sci (Paris). 2024. PMID: 39705562 Review. French.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Melero I, et al. Among authors: de velasco g. Nature. 2024 Dec 11. doi: 10.1038/s41586-024-08305-z. Online ahead of print. Nature. 2024. PMID: 39663448
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
Panian J, Zhong C, Choi SH, Ly K, Quinn R, Ferrier E, Saad E, Saliby RM, Malvar C, Pal S, Ebrahimi H, Tran B, Jude E, Lalani AK, Suarez C, Velasco G, Kanesvaran R, Zarba M, Liow E, El Hajj Chehade R, Choueiri TK, Heng DYC, McKay RR. Panian J, et al. Among authors: velasco g. Eur Urol Focus. 2024 Dec 7:S2405-4569(24)00257-8. doi: 10.1016/j.euf.2024.11.011. Online ahead of print. Eur Urol Focus. 2024. PMID: 39648092
378 results